208 related articles for article (PubMed ID: 38651414)
21. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Groenendijk FH; Mellema WW; van der Burg E; Schut E; Hauptmann M; Horlings HM; Willems SM; van den Heuvel MM; Jonkers J; Smit EF; Bernards R
Int J Cancer; 2015 Mar; 136(6):1434-44. PubMed ID: 25080865
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
[TBL] [Abstract][Full Text] [Related]
24. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
[TBL] [Abstract][Full Text] [Related]
25. NSCLC drug targets acquire new visibility.
Friedrich MJ
J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
[No Abstract] [Full Text] [Related]
26. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.
Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Song Y; Shi Y
Eur J Clin Pharmacol; 2013 Feb; 69(2):151-9. PubMed ID: 22729611
[TBL] [Abstract][Full Text] [Related]
27. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
[TBL] [Abstract][Full Text] [Related]
28. VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
Kuiper JL; Lind JS; Groen HJ; Roder J; Grigorieva J; Roder H; Dingemans AM; Smit EF
Br J Cancer; 2012 Nov; 107(11):1820-5. PubMed ID: 23079575
[TBL] [Abstract][Full Text] [Related]
29. Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
Kutkowska J; Strzadala L; Rapak A
Cancer Sci; 2017 Nov; 108(11):2265-2272. PubMed ID: 28846180
[TBL] [Abstract][Full Text] [Related]
30. Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective.
Shukla SK; Gupta V
Ther Deliv; 2020 Apr; 11(4):213-215. PubMed ID: 31937209
[No Abstract] [Full Text] [Related]
31. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
[TBL] [Abstract][Full Text] [Related]
32. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Horn L; Sandler AB
Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
[TBL] [Abstract][Full Text] [Related]
33. [Lung cancer].
Fischer B; Buhl R
Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
35. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
Yang X; Pan X; Cheng X; Cheng Y; Kuang Y
Int J Clin Pharm; 2015 Dec; 37(6):1047-56. PubMed ID: 26173936
[TBL] [Abstract][Full Text] [Related]
36. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Halliday PR; Blakely CM; Bivona TG
Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
[TBL] [Abstract][Full Text] [Related]
37. Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Tiseo M; Franciosi V; Ardizzoni A
Ann Oncol; 2006 Mar; 17 Suppl 2():ii55-57. PubMed ID: 16608985
[No Abstract] [Full Text] [Related]
38. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Gridelli C; Morgillo F; Favaretto A; de Marinis F; Chella A; Cerea G; Mattioli R; Tortora G; Rossi A; Fasano M; Pasello G; Ricciardi S; Maione P; Di Maio M; Ciardiello F
Ann Oncol; 2011 Jul; 22(7):1528-1534. PubMed ID: 21212155
[TBL] [Abstract][Full Text] [Related]
39. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
